ArticleSchizophrenia (Heidelberg, Germany)2025
Decreased levels of platelet-derived growth factor subtypes and superoxide dismutase isoenzymes in early-onset schizophrenia.
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset schizophrenia (EOS) patients are at greater risk of poor long-term outcomes compared to later-onset patients, so it is essential to identify unique pathomechanisms and prognostic biomarkers for this EOS patient group. Deficits in neurotrophic and oxidative stress resistance are implicated in EOS, so this study investigated associations of EOS risk with peripheral blood platelet-derived growth factor (PDGF) subtype concentrations and superoxide dismutase (SOD) isoenzyme activities. Serum PDGF subtype concentrations and plasma SOD isoenzyme activities were measured in 99 first-episode drug-naïve EOS patients (ages 12-18 years) and 40 matched healthy controls (HCs). Disease severity was assessed using the five-factor model of the Positive and Negative Syndrome Scale (positive, negative, cognitive, excitement/hostility, and anxiety/depression). Serum PDGF-AB and PDGF-BB concentrations, as well as plasma total (T)-SOD and Mn-SOD activities, were significantly lower in EOS patients than HCs (all, P < 0.001 except for T-SOD, where P = 0.003). Serum PDGF-AB concentration was positively correlated with plasma Mn-SOD activity (r = 0.267, P = 0.007), while serum PDGF-BB concentration was negatively correlated with cognitive symptom severity (r = -0.406, P < 0.001), and T-SOD activity was negatively correlated with excitement/hostility symptom severity (r = -0.354, P < 0.001). Multivariate analysis with dichotomized factors identified low PDGF-AB (RR = 1.788, 95% CI: 1.226-2.608, P = 0.003), low PDGF-BB (RR = 1.758, 95% CI: 1.208-2.558, P = 0.003), and a significant PDGF-AB × Mn-SOD interaction (RR = 1.460, 95% CI: 1.044-2.042, P = 0.027) as independent EOS risk factors, with 44.1%, 43.1%, and 31.5% attributable risk, respectively, and population attributable risk fractions of 34.5%, 33.7%, and 23.6%, respectively. Reduced PDGF and SOD levels may contribute to the earlier onset of schizophrenia symptoms and exacerbate symptom severity. Peripheral blood PDGF concentrations and SOD activities may thus be valuable biomarkers for EOS detection.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.